// App-Quantinova.ai

: Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials

Researchers

Presenter

  • Robert K. Hills

Principal Investigators

  • Alan K. Burnett

  • Rosemary Gale

  • David C. Linch

  • Amanda Gilkes

  • Nigel H. Russell

Medical Centers

  • Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom

  • Blackwaterfoot, Cardiff, United Kingdom

  • UCL Cancer Institute, London, UK

  • Kings College London, London, United Kingdom

  • Cardiff University, Cardiff, United Kingdom

  • Nottingham City Hospital, Nottingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved